Medical education company Pri-Med said on Tuesday that it has entered into a new partnership with the Brain Aneurysm Foundation (BAF) to deliver "Update in Diagnosis and Management of Intracranial Aneurysms for Primary Health Care Providers" at Pri-Med Midwest in Rosemont, IL on 10 October 2018.
During the medical session, Sepideh Amin-Hanjani, MD, University of Illinois at Chicago, will address how to recognise signs of an aneurysm rupture, when to make a referral and order appropriate imaging, and best practices for educating the patient about the risk factors for aneurysm formation and rupture.
According to the company, one in 50 people in the US has an unruptured brain aneurysm and 30,000 of them rupture every year. Despite low frequency, brain aneurysms are high in mortality, because the lack of a timely diagnosis often leads to death.
This session will focus on the importance of proper diagnosis and scanning and faculty will discuss treatment options to use in practice to meet the need for early detection of brain aneurysm.
Brain Aneurysm Foundation (BAF) is a non-profit organization dedicated to providing critical awareness, education, support, advocacy, and research funding to reduce the incidence of brain aneurysm ruptures.
AFYREN ingredient enables global launch of natural propionic acid skincare product
Fresenius acquires remaining stake in mAbxience
Lilly reports positive 48-week Phase 2b resu;ts for EloraTZP
Merck reports positive Phase 2b results for tulisokibart in hidradenitis suppurativa
Genentech's fenebrutinib receives FDA priority review for multiple sclerosis
Takeda reports positive Phase 3 psoriasis results for zasocitinib versus deucravacitinib
Oxurion in talks to acquire Eclevar's MedTech CRO business and assets
DBV Technologies submits FDA application for VIASKIN Peanut Patch in children
AstraZeneca invests USD2bn in Summit Therapeutics to advance ADC and cancer-drug combinations
BRC Therapeutics participates in regulators' workshop advancing botanical drug development
Viking Therapeutics closes offerings of common stock and convertible senior notes
Ascletis reports positive results from ASC50 clinical study for treatment of plaque psoriasis
4basebio announces Phase I cell therapy programme partnership with TriLink